INFLIXIMAB and PRODUCT USE ISSUE

13,140 reports of this reaction

1.7% of all INFLIXIMAB reports

#9 most reported adverse reaction

Overview

PRODUCT USE ISSUE is the #9 most commonly reported adverse reaction for INFLIXIMAB, manufactured by Janssen Biotech, Inc.. There are 13,140 FDA adverse event reports linking INFLIXIMAB to PRODUCT USE ISSUE. This represents approximately 1.7% of all 769,608 adverse event reports for this drug.

Patients taking INFLIXIMAB who experience product use issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PRODUCT USE ISSUE13,140 of 769,608 reports

PRODUCT USE ISSUE is a less commonly reported adverse event for INFLIXIMAB, but still significant enough to appear in the safety profile.

Other Side Effects of INFLIXIMAB

In addition to product use issue, the following adverse reactions have been reported for INFLIXIMAB:

DRUG INEFFECTIVE — 38,907 reports
OFF LABEL USE — 36,963 reports
INFUSION RELATED REACTION — 18,649 reports
CONDITION AGGRAVATED — 18,303 reports
RHEUMATOID ARTHRITIS — 18,137 reports
PAIN — 18,109 reports
ARTHRALGIA — 16,852 reports
FATIGUE — 16,118 reports
RASH — 12,886 reports
DRUG INTOLERANCE — 12,164 reports

Other Drugs Associated with PRODUCT USE ISSUE

The following drugs have also been linked to product use issue in FDA adverse event reports:

ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE ALUMINUM HYDROXIDE ARFORMOTEROL TARTRATE ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, OXYBENZONE BAYER GENUINE ASPIRIN BREXPIPRAZOLE BRIVARACETAM BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE BUTENAFINE HYDROCHLORIDE CAMPHOR AND MENTHOL CAMPHOR, EUCALYPTUS OIL, MENTHOL CAMPHOR (SYNTHETIC), EUCALYPTUS OIL, AND MENTHOL CRISABOROLE DEUTETRABENAZINE DICLOFENAC SODIUM ESMOLOL HYDROCHLORIDE

Frequently Asked Questions

Does INFLIXIMAB cause PRODUCT USE ISSUE?

PRODUCT USE ISSUE has been reported as an adverse event in 13,140 FDA reports for INFLIXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PRODUCT USE ISSUE with INFLIXIMAB?

PRODUCT USE ISSUE accounts for approximately 1.7% of all adverse event reports for INFLIXIMAB, making it a notable side effect.

What should I do if I experience PRODUCT USE ISSUE while taking INFLIXIMAB?

If you experience product use issue while taking INFLIXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

INFLIXIMAB Full Profile All Drugs Causing PRODUCT USE ISSUE Janssen Biotech, Inc. Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.